Solasta Ventures
Home Approach Portfolio
News Team Hatchery Contact
HomeApproachPortfolio
Solasta Ventures
NewsTeamHatcheryContact
Trefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study Data
Nia JulianSeptember 30, 2022
Facebook0 Twitter Pinterest0 0 Likes
Previous

AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline

Nia JulianDecember 6, 2022
Next

Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies

Nia JulianSeptember 21, 2022

© 2020 Solasta Ventures. All Rights Reserved.